Feverfew (Tanacetum parthenium)

Feverfew (Tanacetum parthenium) is a European herb containing parthenolide, a sesquiterpene lactone that demonstrates Fe²⁺-chelating activity and anti-inflammatory properties. The herb also provides flavonoids including luteolin (0.84% d.w.) and apigenin (0.68% d.w.) that contribute to its antioxidant mechanisms.

Origin & History

Feverfew (Tanacetum parthenium) is a perennial herb native to the Balkan Peninsula and southern Europe, now widely naturalized globally, belonging to the Asteraceae family. The aerial parts, particularly leaves rich in glandular trichomes, are harvested and processed via solvent extraction (ethanol or water) or steam distillation for essential oils.

Historical & Cultural Context

Feverfew has been used in European traditional medicine for centuries to treat migraines, fevers, arthritis, and menstrual issues. Its pharmacological significance is attributed to sesquiterpene lactones (particularly parthenolide), flavonoids, and essential oils.

Health Benefits

• Antioxidant properties - Contains parthenolide with Fe²⁺-chelating activity and flavonoids like luteolin (0.84% d.w.) and apigenin (0.68% d.w.) [preliminary evidence only]
• Traditional migraine support - Used historically in European medicine, though no clinical trials provided in available research
• Antimicrobial activity - Preclinical data suggests potential, but human evidence not available
• Traditional fever reduction - Historical use documented, but no clinical validation in provided sources
• Menstrual support - Traditional application noted, but lacks modern clinical evidence

How It Works

Parthenolide, feverfew's primary bioactive compound, chelates Fe²⁺ ions and inhibits nuclear factor-kappa B (NF-κB) signaling pathways, reducing inflammatory mediator production. The flavonoids luteolin and apigenin scavenge free radicals through phenolic hydroxyl groups and modulate antioxidant enzyme activity. These compounds may also influence serotonin receptors and platelet aggregation, though specific receptor interactions require further research.

Scientific Research

The available research lacks human clinical trials, RCTs, or meta-analyses on feverfew efficacy. Current evidence is limited to preclinical studies on chemical composition, antioxidant properties, and antimicrobial activity, with no PubMed PMIDs provided for human studies.

Clinical Summary

Current clinical evidence for feverfew remains limited, with most research consisting of preliminary in vitro studies examining antioxidant capacity and compound identification. Traditional use studies from European medicine document historical migraine applications, but no randomized controlled trials with specific dosages, sample sizes, or quantified outcomes are available in the current research base. The evidence strength is considered preliminary, requiring controlled human studies to establish therapeutic efficacy. Bioactive compound concentrations have been quantified through analytical chemistry methods but lack clinical correlation.

Nutritional Profile

Feverfew (Tanacetum parthenium) is consumed primarily as a medicinal herb rather than a dietary staple, so macronutrient contributions at typical doses (50–150 mg dried leaf/day) are negligible. Bioactive compounds dominate its nutritional-pharmacological profile: Sesquiterpene lactones are the primary actives, with parthenolide being the most characterized (0.2–0.9% d.w. in dried leaves, varying significantly by chemotype and geographic origin); parthenolide exhibits Fe²⁺-chelating (antioxidant) activity and is considered the principal marker compound. Flavonoids are well-documented, including luteolin at approximately 0.84% d.w. and apigenin at approximately 0.68% d.w., both with established antioxidant and anti-inflammatory preclinical profiles; chrysoeriol and quercetin derivatives are also reported in smaller quantities. Volatile oils (0.02–0.07% d.w.) include camphor, camphene, and bornyl acetate as major constituents. Polyacetylenes and melatonin (trace levels, ~2.45 µg/g d.w.) have been detected in leaf tissue. Conventional micronutrients (vitamins A, C, calcium, iron) are present at low but non-zero levels in the whole herb, though at medicinal doses these contributions are clinically insignificant. Dietary fiber is present in whole-leaf preparations but unquantified at therapeutic doses. Bioavailability note: Parthenolide bioavailability is considered moderate; it is lipophilic and absorption may be enhanced with dietary fat, but undergoes significant first-pass metabolism; standardized extracts (≥0.2% parthenolide) are used in research to control dose variability.

Preparation & Dosage

No clinically studied dosage ranges or standardization details are available in the current research. Standardized extracts often target parthenolide content (0.2-1.2% in leaves), but human dosing studies are absent. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Magnesium, Riboflavin (B2), Butterbur, Ginger, CoQ10

Safety & Interactions

Feverfew may cause mouth ulcers, gastrointestinal upset, and contact dermatitis in sensitive individuals. The herb can interact with anticoagulant medications due to potential effects on platelet function and should be avoided with warfarin or similar blood thinners. Pregnant and breastfeeding women should avoid feverfew as safety data is insufficient and traditional use suggests uterine stimulant properties. Individuals allergic to plants in the Asteraceae family (ragweed, chrysanthemums, marigolds) may experience cross-reactive allergic responses.